Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis

Journal of Autoimmunity

Volumn 74, Issue , 2016, Pages 94-105

  Gatto, Mariele ^a   Saccon, Francesca ^a   Zen, Margherita ^a   Bettio, Silvano ^a   Iaccarino, Luca ^a   Punzi, Leonardo ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti CD20; Biologics; BLyS; Lupus nephritis; Outcome measure; Registries

Indexed keywords

ABATACEPT; ATACICEPT; BELIMUMAB; CYTOKINE ANTIBODY; INTERFERON ANTIBODY; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT FAILURE; TREATMENT OUTCOME;

B-LYMPHOCYTES; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84978472326     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.06.014     Document Type: Review

References (115)

1. [1] Doria, A., Iaccarino, L., Ghirardello, A., Zampieri, S., Arienti, S., Sarzi-Puttini, P., et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med. 119 (2006), 700–706.
2. [2] Costenbader, K., Desai, A., Alarcón, G., Hiraki, L., Shaykevich, T., Brookhart, M., et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 63 (2011), 1681–1688.
3. [3] Ward, M., Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J. Rheumatol. 36 (2009), 63–67.
4. [4] Gladman, D., Urowitz, M., Rahman, P., Ibanez, D., Tam, L., Accrual of organ damage over time in patients with systemic lupus erythematosus. J. Rheumatol. 30 (2003), 1955–1959.
5. [5] Gatto, M., Kiss, E., Naparstek, Y., Doria, A., In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med., 17, 2014 12:30.
6. [6] DeWitt, E., Brunner, H., The landscape of comparative effectiveness research in rheumatology. Nat. Rev. Rheumatol. 10 (2014), 57–62.
7. [7] Lateef, A., Petri, M., Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther., 14(Suppl. 4), 2012, S4.
8. [8] Doria, A., Gatto, M., Zen, M., Iaccarino, L., Punzi, L., Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun. Rev. 13 (2014), 770–777.
9. [9] Rahman, P., Gladman, D., Urowitz, M., Hallett, D., Tam, L., Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 10 (2001), 93–96.
10. [10] Nossent, J., Kiss, E., Rozman, B., Pokorny, G., Vlachoyiannopoulos, P., Olesinska, M., et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 19 (2010), 949–956.
11. [11] Doria, A., Gatto, M., Iaccarino, L., Punzi, L., Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. Lupus 24 (2015), 507–515.
12. [12] Urowitz, M., Feletar, M., Bruce, I., Ibañez, D., Gladman, D., Prolonged remission in systemic lupus erythematosus. J. Rheumatol. 32 (2005), 1467–1472.
13. [13] Steiman, A., Gladman, D., Ibañez, D., Urowitz, M., Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J. Rheumatol. 37 (2010), 1822–1827.
14. [14] Zen, M., Iaccarino, L., Gatto, M., Bettio, S., Nalotto, L., Ghirardello, A., et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann. Rheum. Dis. 74 (2015), 2117–2122.
15. [15] Alarcón-Segovia, D., Tumlin, J., Furie, R., McKay, J., Cardiel, M., Strand, V., et al. LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48 (2003), 442–454.
16. [16] Cardiel, M., Tumlin, J., Furie, R., Wallace, D., Joh, T., Linnik, M., LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 58 (2008), 2470–2480.
17. [17] Ginzler, E., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther., 14, 2012, R33.
18. [18] Rovin, B., Furie, R., Latinis, K., Looney, R., Fervenza, F., Sanchez-Guerrero, J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study. Arthritis Rheum. 64 (2012), 1215–1226.
19. [19] Mysler, E., Spindler, A., Guzman, R., Bijl, M., Jayne, D., Furie, R.A., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65 (2013), 2368–2379.
20. [20] Furie, R., Nicholls, K., Cheng, T., Houssiau, F., Burgos-Vargas, R., Chen, S., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66 (2014), 379–389.
21. [21] ACCESS Trial Group, Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. 66 (2014), 3096–3104.
22. [22] Kalunian, K., Davis, J. Jr., Merrill, J.T., Totoritis, M., Wofsy, D., IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 (2002), 3251–3258.
23. [23] Wallace, D., Stohl, W., Furie, R., Lisse, J., McKay, J., Merrill, J.T., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61 (2009), 1168–1178.
24. [24] Merrill, J.T., Burgos-Vargas, R., Westhovens, R., Chalmers, A., D'Cruz, D., Wallace, D., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62 (2010), 3077–3087.
25. [25] Merrill, J.T., Neuwelt, C., Wallace, D., Shanahan, J., Latinis, K., Oates, J., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62 (2010), 222–233.
26. [26] Navarra, S.V., Guzmàn, R., Gallacher, A., Hall, S., Levy, G., Jimenez, R., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731.
27. [27] Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D., Tegzova, D., et al. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis Rheum. 63 (2011), 3918–3930.
28. [28] Zimmer, R., Scherbarth, H., Rillo, O., Gomez-Reino, J., Muller, S., Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann. Rheum. Dis. 72 (2013), 1830–1835.
29. [29] Wallace, D., Gordon, C., Strand, V., Hobbs, K., Petri, M., Kalunian, K., et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatol. Oxf. 52 (2013), 1313–1322.
30. [30] Wallace, D., Kalunian, K., Petri, M., Strand, V., Houssiau, F., Pike, M., et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. 73 (2014), 183–190.
31. [31] Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C., Wofsy, D., Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74 (2015), 2006–2015.
32. [32] Kalunian, K., Merrill, J.T., Maciuca, R., McBride, J., Townsend, M., Wei, X., et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75 (2016), 196–202.
33. [33] R. Furie, J.T. Merrill, V. Werth, M. Kamashta, K. Kalunian, P. Brohawn, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe SLE. Abstract no. 3223 presented at the ACR/ARHP annual meeting, San Francisco, CA, November 6–11, 2015.
34. [34] W. Stohl, A. Schwarting, M. Okada, M. Scheinberg, A. Doria, A. Hammer, et al. A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE). Abstract no. 3218 presented at the ACR/ARHP annual meeting, San Francisco, CA, November 6–11, 2015.
35. [35] Urowitz, M., Isenberg, D., Wallace, D., Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus. Sci. Med., 11, 2015, e000104.
36. [36] Furie, R., Leon, G., Thomas, M., Petri, M., Chu, A., Hislop, C., et al. PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann. Rheum. Dis. 74 (2015), 1667–1675.
37. [37] Isenberg, D., Petri, M., Kalunian, K., Tanaka, Y., Urowitz, M., Hoffman, R., et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75 (2016), 323–331.
38. [38] Merrill, J.T., van Vollenhoven, R., Buyon, J., Furie, R., Stohl, W., Morgan-Cox, M., et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75 (2016), 332–340.
39. [39] Khamashta, M., Merrill, J.T., Werth, V., Furie, R., Kalunian, K., Illei, G., et al. CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis., 2016 Mar 23, 10.1136/annrheumdis-2015-208562 pii: annrheumdis-2015-208562. (Epub ahead of print) PubMed PMID: 27009916.
40. [40] Thanou, A., Merrill, J.T., Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat. Rev. Rheumatol. 10 (2014), 23–34.
41. [41] Petri, M., Epidemiology of systemic lupus erythematosus. Best. Pract. Res. Clin. Rheumatol. 16 (2002), 847–858.
42. [42] Gatto, M., Zen, M., Ghirardello, A., Bettio, S., Bassi, N., Iaccarino, L., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun. Rev. 12 (2013), 523–536.
43. [43] Zen, M., Bassi, N., Canova, M., Bettio, S., Gatto, M., et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin. Exp. Rheumatol. 30 (2012), 856–863.
44. [44] Barr, S., Zonana-Nachach, A., Madger, L., Petri, M., Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 42 (1999), 2682–2688.
45. [45] Davies, R., Sangle, S., Jordan, N., Aslam, L., Lewis, M., Wedgwood, R., et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 22 (2013), 574–582.
46. [46] Reddy, V., Jayne, D., Close, D., Isenberg, D., B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res. Ther., 15(Suppl. 1), 2013, S2.
47. [47] Furie, R., Petri, M., Wallace, D., Ginzler, E., Merrill, J.T., Stohl, W., et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61 (2009), 1143–1151.
48. [48] Hiepe, F., Radbruch, A., Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12 (2016), 232–240.
49. [49] Duxbury, B., Combescure, C., Chizzolini, C., Rituximab in systemic lupus erythematosus: an updated systematic review and metanalysis. Lupus 22 (2013), 1489–1503.
50. [50] Pepper, R., Griffith, M., Kirwan, C., Levy, J., Taube, D., Pusey, C., et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol. Dial. Transpl. 24 (2009), 3717–3723.
51. [51] Ezeonyeji, A., Isenberg, D., Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 52 (2012), 476–481.
52. [52] Roccatello, D., Sciascia, S., Baldovino, S., Rossi, D., Alpa, M., Naretto, C., et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmun. Rev. 14 (2015), 1123–1130.
53. [53] Manou-Stathopolou, S., Robson, M., Risk of clinical deterioration in patients with lupus nephritis using rituximab. Lupus., 2016 Apr 15 pii: 0961203316641768. (Epub ahead of print) PubMed PMID: 27084027.
54. [54] Tanaka, Y., Takeuchi, T., Miyasaka, N., Sumida, T., Mimori, T., Koike, T., et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod. Rheumatol. 26 (2016), 80–86.
55. [55] Li, E., Tam, L., Zhui, T., Li, M., Kwok, C., Li, T.K., et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology 48 (2009), 892–898.
56. [56] Weidenbusch, M., Römmele, C., Schröttle, A., Anders, H., Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol. Dial. Transpl. 28 (2013), 106–111.
57. [57] Lightstone, L., The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum. 64 (2012), 962–965.
58. [58] Galarza-Maldonado, C., Kourilovitch, M., Molineros, J., Cardiel, M., Zurita, L., Soroka, N., et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun. Rev. 10 (2010), 108–111.
59. [59] Beckwith, H., Lightstone, L., Rituximab in systemic lupus erythematosus and lupus nephritis. Nephron. Clin. Pract. 128 (2014), 250–254.
60. [60] Catapano, F., Chaudhry, A., Jones, R., Smith, K., Jayne, D., Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol. Dial. Transpl. 25 (2010), 3586–3592.
61. [61] Melander, C., Sallée, M., Trolliet, P., Candon, S., Belenfant, X., Daugas, E., et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 4 (2009), 579–587.
62. [62] Boletis, J., Marinaki, S., Skalioti, C., Lionaki, S., Iniotaki, A., Sfikakis, P., Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol. Dial. Transpl. 24 (2009), 2157–2160.
63. [63] Moroni, G., Gallelli, B., Sinico, R., Romano, G., Sinigaglia, L., Messa, P., Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann. Rheum. Dis. 71 (2012), 1751–1752.
64. [64] Fernández-Nebro, A., de la Fuente, J., Carreño, L., Izquierdo, M., Tomero, E., Rúa-Figueroa, I., et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 21 (2012), 1063–1076.
65. [65] Condon, M., Ashby, D., Pepper, R., Cook, H., Levy, J., Griffith, M., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72 (2013), 1280–1286.
66. [66] Tanaka, Y., Yamamoto, K., Takeuchi, T., Nishimoto, N., Miyasaka, N., Sumida, T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17 (2007), 191–197.
67. [67] Jónsdóttir, T., Gunnarsson, I., Risselada, A., Henriksson, E., Klareskog, L., van Vollenhoven, R., Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67 (2008), 330–334.
68. [68] Reynolds, J., Toescu, V., Yee, C., Prabu, A., Situnayake, D., Gordon, C., Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18 (2009), 67–73.
69. [69] Lu, T., Ng, K., Cambridge, G., Leandro, M., Edwards, J., Ehrenstein, M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61 (2009), 482–487.
70. [70] Vital, E., Dass, S., Buch, M., Henshaw, K., Pease, C., Martin, M., et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 63 (2011), 3038–3047.
71. [71] Turner-Stokes, T., Lu, T., Ehrenstein, M., Giles, I., Rahman, A., Isenberg, D., The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology 50 (2011), 1401–1408.
72. [72] Ramos-Casals, M., Soto, M., Cuadrado, M., Khamashta, M., Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18 (2009), 767–776.
73. [73] Merrill, J.T., Buyon, J., Furie, R., Latinis, K., Gordon, C., Hsieh, H., et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20 (2011), 709–716.
74. [74] Lazarus, M., Turner-Stokes, T., Chavele, K., Isenberg, D., Ehrenstein, M., B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology 51 (2012), 1208–1215.
75. [75] Cancro, M., D'Cruz, D., Khamashta, M., The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Invest. 119 (2009), 1066–1073.
76. [76] Carter, L., Isenberg, D., Ehrenstein, M., Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65 (2013), 2672–2679.
77. [77] Cambridge, G., Isenberg, D., Edwards, J., Leandro, M., Migone, T., Teodorescu, M., Stohl, W., B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67 (2008), 1011–1016.
78. [78] Simonetta, F., Allali, D., Roux-Lombard, P., Chizzolini, C., Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Jt. Bone Spine., 2016 May 26, 10.1016/j.jbspin.2016.01.008 pii: S1297-319X(16)30020-3. (Epub ahead of print) PubMed PMID: 27238199.
79. [79] Kraaij, T., Huizinga, T., Rabelink, T., Teng, Y., YK. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology 53 (2014), 2122–2124.
80. [80] Iaccarino, L., Bartoloni, E., Carli, L., Ceccarelli, F., Conti, F., De Vita, S., et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin. Exp. Rheumatol. 33 (2015), 449–456.
81. [81] Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62 (2010), 2458–2466.
82. [82] Witt, M., Grunke, M., Proft, F., Baeuerle, M., Aringer, M., Burmester, G., et al. German Registry of Autoimmune Diseases (GRAID) Investigators. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 22 (2013), 1142–1149.
83. [83] Díaz-Lagares, C., Croca, S., Sangle, S., Vital, E., Catapano, F., Martínez-Berriotxoa, A., et al. UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun. Rev. 11 (2012), 357–364.
84. [84] Vincent, F., Morand, E., Schneider, P., Mackay, F., The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 10 (2014), 365–373.
85. [85] Jacob, C., Guo, S., Jacob, N., Pawar, R., Putterman, C., Quinn, W. 3rd, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 64 (2012), 1610–1619.
86. [86] Davidson, A., The rationale for BAFF inhibition in systemic lupus erythematosus. Curr. Rheumatol. Rep. 14 (2012), 295–302.
87. [87] Iaccarino, L., Bettio, S., Reggia, R., Zen, M., Frassi, M., Andreoli, L., et al. Belimumab decreases flare frequency and hinders the expected damage progression in patients with active systemic lupus erythematosus: data from clinical practice setting. Arthritis Res. Ther., 2016 (Epub ahead of print).
88. [88] Bruce, I., Urowitz, M., van Vollenhoven, R., Aranow, C., Fettiplace, J., Oldham, M., et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus., 2016 Mar 1 pii: 0961203315625119. (Epub ahead of print), PubMed PMID: 26936891.
89. [89] Ginzler, E., Wallace, D., Merrill, J.T., Furie, R., Stohl, W., Chatham, W., et al. LBSL02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J. Rheumatol. 41 (2014), 300–309.
90. [90] van Vollenhoven, R., Petri, M., Wallace, D., Roth, D., Molta, C., Hammer, A., et al. Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. Arthritis Rheumatol., 2016 Mar 18, 10.1002/art.39682 (Epub ahead of print) PubMed PMID: 26992106.
91. [91] van Vollenhoven, R., Petri, M., Cervera, R., Roth, D., Ji, B., Kleoudis, C., et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71 (2012), 1343–1349.
92. [92] Houssiau, F., Doria, A., Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?. Ann. Rheum. Dis. 75 (2016), 321–322.
93. [93] Salazar-Camarena, D., Ortiz-Lazareno, P., Cruz, A., Oregon-Romero, E., Machado-Contreras, J., Muñoz-Valle, J., et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus 25 (2016), 582–592.
94. [94] Coquery, C., Loo, W., Wade, N., Bederman, A., Tung, K., Lewis, J., et al. BAFF regulates follicular helper T cells and affects their accumulation and interferon production in autoimmunity. Arthritis Rheumatol. 67 (2015), 773–784.
95. [95] Stohl, W., Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells. Arthritis Rheumatol. 67 (2015), 612–615.
96. [96] Boumpas, D., Furie, R., Manzi, S., Illei, G., Wallace, D., Balow, J., et al. BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48 (2003), 719–727.
97. [97] Wosfy, D., Hillson, J.L., Diamond, B., Abatacept for lupus nephritis. Alternative definitions of complete response support conflicting conclusions. Arthritis Rheumatol. 64 (2012), 3660–3665.
98. [98] Rovin, B., Parikh, S., Lupus nephritis: the evolving role of novel therapeutics. Am. J. Kidney Dis. 63 (2014), 677–690.
99. [99] Mathian, A., Hie, M., Cohen-Aubart, F., Amoura, Z., Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75 (2015), 835–846.
100. [100] Lindau, D., Mussard, J., Rabsteyn, A., Ribon, M., Kötter, I., Igney, A., et al. TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann. Rheum. Dis. 73 (2014), 2199–2207.
101. [101] Dall'Era, M., Cardarelli, P., Preston, B., Witte, A., Davis, J. Jr., Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 64 (2005), 1692–1697.
102. [102] Tucci, M., Quatraro, C., Lombardi, L., Pellegrino, C., Dammacco, F., Silvestris, F., Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58 (2008), 251–262.
103. [103] C. Morehouse, L. Chang, L. Wang, P. Brohawan, S. Uead, G. Illei, et al. Target modulation of a type I interferon gene signature with sifalimumab or anifrolumab in SLE patients in two open labels phase II Japanese trials. Abstract no. 719 presented at the ACR/ARHP annual meeting, Boston, MA, November 15-19, 2014.
104. [104] Lauwerys, B., Hachulla, E., Spertini, F., Lazaro, E., Jorgensen, C., Mariette, X., et al. Down-regulation of interferon signature in SLE patients by active immunization with interferon alpha kinoid. Arthritis Rheum. 64 (2013), 447–456.
105. [105] Peterson, E., Robertson, A., Emlen, m. W., Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 5 (1996), 571–575.
106. [106] Klashman, D., Martin, R., Martínez-Maza, O., Stevens, R., In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum. 34 (1991), 276–286.
107. [107] Liang, B., Gardner, D., Griswold, D., Bugelski, P., Song, X., Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119 (2006), 296–305.
108. [108] Kiberd, B., Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J. Am. Soc. Nephrol. 4 (1993), 58–61.
109. [109] Rovin, B., van Vollenhoven, R., Aranow, C., Wagner, C., Gordon, R., Zhuang, Y., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol., 2016 Apr 25, 10.1002/art.39722 (Epub ahead of print) PubMed PMID: 27110697.
110. [110] Illei, G., Shirota, Y., Yarboro, C., Daruwella, J., Tackey, E., Takada, K., et al. Tocilizumab in systemic lupus erythematosus. Arthritis Rheum. 62 (2010), 542–552.
111. [111] Wosfy, D., Hillson, J., Diamond, B., Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 65 (2013), 1586–1591.
112. [112] Petri, M., Disease activity assessment in SLE: do we have the right instruments?. Ann. Rheum. Dis., 66(Suppl. 3), 2007 iii61–4.
113. [113] Corapi, K., Dooley, M., Pendergraft, W. 3rd, Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res. Ther., 28, 2015 17:110.
114. [114] Miles, A., Pope, J.E., A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE. Clin. Exp. Rheumatol. 33 (2015), 671–680.
115. [115] Dall'Era, M., Wofsy, D., Systemic lupus erythematosus clinical trials-an interim analysis. Nat. Rev. Rheumatol. 5 (2009), 348–351.